|
Post by falconquest on Jul 25, 2017 18:10:10 GMT -5
If you forget everything you know about Afrezza, Mike, commercials, long term potential and ask yourself, based on the facts about this company, that they are pretty much on a slow march toward running out of cash in October, would you invest in this company? It doesn't matter what the potential is folks, we're out of cash unless Mike can pull a rabbit out of his hat. I just don't see any reason to be invested at this point. I hate to see those who have been here through thick and thin lose their investment completely in Mannkind. Please take a hard look at what we are facing and ask yourself if you're willing to risk it all. In the end, if you held and lost, no one will give a damn. If you sell and have some capital left then you can at least move on to other opportunities. I'm not advocating anything other than taking a hard look at Mannkind and making the decision to ride it out or at least preserve some capital. I know you think it noble to hold but as I mentioned, no one will care if this fails. Perhaps Matt had enough and wanted out. He gave it his best shot and moved on. Think about Diane Palumbo and Andrea Leone Bay, why did they leave? All I'm saying is take a hard look folks. The best to you. Or wait a little closer to the moment of truth and then buy some short term insurance in the form of puts? Deerfield may be plan B Mary. I'm guessing the plan A may be to sell all rights to TS... with that other firm shopping it. As for some expecting equity raise... our market cap just doesn't seem to support it at this point. As someone with a fair amount of experience explained here there is only so much stock the market can absorb from underwriters and were at a point where that amount is likely less than our cash burn rate. Bottom line is that it's not a no-brainer that dilutive equity round is possible now. I'd love to here someone with experience say otherwise. I would agree except they haven't found anyone much interested in Technosphere to date have they? We all know about Hakan's "call me" and Matt's "embarrassment of riches" comments.
|
|
|
Post by sayhey24 on Jul 25, 2017 18:30:25 GMT -5
For those who forgot where cash may come from before the end of this year... 1. Brazil distribution 2. UAE distribution 3. Locust Walk finds strategic partner for TS 4. One Drop 5. RLS 6. Alternative financing options that are non dilutive (ask new CFO for details) While I believe the UAE deal is real, and Mike mentioned India in a recent interview, I always liked Israel and China. Sports posted a tweet on another thread about Sierra world which has always been a questionable outfit but it reminded me of Roche sierraworldequityreview.blogspot.com/2017/07/wasting-no-timemannkind-corp-mnkd-new.htmlThis is from Reuters last February when the rumor was Roche was getting out of the diabetes space but instead decided to double down and is looking to do some deals. www.reuters.com/article/us-roche-holding-divestiture-idUSKBN15G3EQThe thing about Roche is they see Asia as their primary market with China being huge.
|
|
|
Post by akemp3000 on Jul 25, 2017 20:30:37 GMT -5
Could be rumors are originating from Locust Walk talking to multiple drug companies including Roche. Different drug companies are more successful than others doing business in different countries. Mannkind partnerships are like a box of chocolates...you never know what you're gonna get! The most recent three were certainly a total surprise to this MB...Biomm, One Drop and Locust Walk. While these haven't yet produced revenue, who's to say they, or the next ones won't, such as the Middle East?
|
|
|
Post by #NoMoreNeedles on Jul 26, 2017 7:14:09 GMT -5
|
|
|
Post by agedhippie on Jul 26, 2017 7:35:26 GMT -5
They were already a major investor in mySugr. Roche is going after the same spot that One Drop is but while an awful lot larger budget and the added advantage of being a manufacturer rather than a reseller.
|
|
|
Post by oldfishtowner on Jul 26, 2017 8:56:57 GMT -5
They were already a major investor in mySugr. Roche is going after the same spot that One Drop is but while an awful lot larger budget and the added advantage of being a manufacturer rather than a reseller. So, should MNKD buy out One Drop? It would be a good excuse to increase authorized shares for an equity offering along with the shares needed for a stock swap with One Drop.
|
|
|
Post by peppy on Jul 26, 2017 9:18:08 GMT -5
They were already a major investor in mySugr. Roche is going after the same spot that One Drop is but while an awful lot larger budget and the added advantage of being a manufacturer rather than a reseller. So, should MNKD buy out One Drop? It would be a good excuse to increase authorized shares for an equity offering along with the shares needed for a stock swap with One Drop. partner. one free afrezza demo kit with one drop prescription.
|
|
|
Post by akemp3000 on Jul 26, 2017 9:44:43 GMT -5
I can't see any BGM device companies such as Dexcom, One Drop, Libre (Abbott) or mySugr (Roche) teaming up with Afrezza in any capacity. These devices monitor BG then look to the world to provide solutions. Teaming up with one would eliminate using their device with all other solutions and could be risky. That said, they all probably know by now that no solution other than Afrezza can provide better results. It's feasible, that one of these could decide to own Afrezza knowing the new team could then produce unmatchable results from any competitor. The great news for us is watching the whole world rapidly shifting to real time-in-range glucose monitoring. This shift will eventually lead to the global paradigm shift to Afrezza we've all been waiting on. Other TS technologies should follow as well.
|
|
|
Post by kbrion77 on Jul 26, 2017 10:05:15 GMT -5
I can't see any BGM device companies such as Dexcom, One Drop, Libre (Abbott) or mySugr (Roche) teaming up with Afrezza in any capacity. These devices monitor BG then look to the world to provide solutions. Teaming up with one would eliminate using their device with all other solutions and could be risky. That said, they all probably know by now that no solution other than Afrezza can provide better results. It's feasible, that one of these could decide to own Afrezza knowing the new team could then produce unmatchable results from any competitor. The great news for us is watching the whole world rapidly shifting to real time-in-range glucose monitoring. This shift will eventually lead to the global paradigm shift to Afrezza we've all been waiting on. Other TS technologies should follow as well. This is a confusing post. Are One Drop and Mannkind not already collaborating for better health outcomes for PWD? I am not a doctor but I don't care how efficient Afrezza works if you have diabetes you still would need a monitoring tool/device, especially T1s. The play would be for Apple to buy out One Drop's app and data interface, Apple finish developing their non-invasive iWatch for BG monitoring and an Afrezza/Apple strategic partnership on complete non-invasive diabetes care.
|
|
|
Post by akemp3000 on Jul 26, 2017 11:51:39 GMT -5
I can't see any BGM device companies such as Dexcom, One Drop, Libre (Abbott) or mySugr (Roche) teaming up with Afrezza in any capacity. These devices monitor BG then look to the world to provide solutions. Teaming up with one would eliminate using their device with all other solutions and could be risky. That said, they all probably know by now that no solution other than Afrezza can provide better results. It's feasible, that one of these could decide to own Afrezza knowing the new team could then produce unmatchable results from any competitor. The great news for us is watching the whole world rapidly shifting to real time-in-range glucose monitoring. This shift will eventually lead to the global paradigm shift to Afrezza we've all been waiting on. Other TS technologies should follow as well. This is a confusing post. Are One Drop and Mannkind not already collaborating for better health outcomes for PWD? I am not a doctor but I don't care how efficient Afrezza works if you have diabetes you still would need a monitoring tool/device, especially T1s. The play would be for Apple to buy out One Drop's app and data interface, Apple finish developing their non-invasive iWatch for BG monitoring and an Afrezza/Apple strategic partnership on complete non-invasive diabetes care. I would imagine all of these BGM device companies are collaborating (sharing knowledge) in some form with multiple drug company solutions that can prove the effectiveness of their devices. I should have been more clear when I used the phrase "teaming up". I meant this in a partnership, money making capacity. I'm not aware this type of partnership exists between Mannkind and One Drop or between any BGM device company and a single drug company.
|
|
Tinkerbell
Researcher
Watcher of the Skies
Posts: 143
|
Post by Tinkerbell on Jul 26, 2017 13:58:06 GMT -5
Or wait a little closer to the moment of truth and then buy some short term insurance in the form of puts? Deerfield may be plan B Mary. I'm guessing the plan A may be to sell all rights to TS... with that other firm shopping it. As for some expecting equity raise... our market cap just doesn't seem to support it at this point. As someone with a fair amount of experience explained here there is only so much stock the market can absorb from underwriters and were at a point where that amount is likely less than our cash burn rate. Bottom line is that it's not a no-brainer that dilutive equity round is possible now. I'd love to here someone with experience say otherwise. I would agree except they haven't found anyone much interested in Technosphere to date have they? We all know about Hakan's "call me" and Matt's "embarrassment of riches" comments. As sincere as all of the above sounds I will speak for myself. I am fully aware of the cash situation MannKind faces and I am prepared to lose my entire investment. All of it. The advise to sell and preserve what little is left of my long term investment 'rings hollow.' Why? If MannKind fails, it fails. I will lose my entire investment afterwhich I will get up, dust myself off and move onto another investment. MannKind is not my only investment. If MannKind doesn't fail, it doesn't fail. My investment will grow over time. Now regarding MannKind the company - itself, I have my opinion about management from C CO, C EO right on to C PO there: A) From 2004 through 2016 - completely inept at not only developing Afrezza but commercializing it too. B) From Feb 2016 through July 26, 2017 - far better suited and properly experienced to commercialize and continue researching not only Afrezza but Technosphere as well. That's all there is. Now, respecting whether the current MannKind management team will secure a partner to support commercialization activities in the US or outside of the US, or, successfully raise money through an equity offering or other means, here is my opinion: Refer to B) above. That's all there is.
|
|
|
Post by n8 on Jul 26, 2017 14:14:11 GMT -5
I would agree except they haven't found anyone much interested in Technosphere to date have they? We all know about Hakan's "call me" and Matt's "embarrassment of riches" comments. As sincere as all of the above sounds I will speak for myself. I am fully aware of the cash situation MannKind faces and I am prepared to lose my entire investment. All of it. The advise to sell and preserve what little is left of my long term investment 'rings hollow.' Why? If MannKind fails, it fails. I will lose my entire investment afterwhich I will get up, dust myself off and move onto another investment. MannKind is not my only investment. If MannKind doesn't fail, it doesn't fail. My investment will grow over time. Now regarding MannKind the company - itself, I have my opinion about management from C CO, C EO right on to C PO there: A) From 2004 through 2016 - completely inept at not only developing Afrezza but commercializing it too. B) From Feb 2016 through July 26, 2017 - far better suited and properly experienced to commercialize and continue researching not only Afrezza but Technosphere as well. That's all there is. Now, respecting whether the current MannKind management team will secure a partner to support commercialization activities in the US or outside of the US, or, successfully raise money through an equity offering or other means, here is my opinion: Refer to B) above. That's all there is. Exactly. A fundamental change is obvious. Many positive things are happening. At this point it is pointless to debate cash burn and what occurred in the past unless you are trying to prevent others from investing, which is not always about the companies books. People's minds are changed through observation and not through argument. Will Rogers
|
|
|
Post by scoy on Jul 26, 2017 15:35:28 GMT -5
As sincere as all of the above sounds I will speak for myself. I am fully aware of the cash situation MannKind faces and I am prepared to lose my entire investment. All of it. The advise to sell and preserve what little is left of my long term investment 'rings hollow.' Why? If MannKind fails, it fails. I will lose my entire investment afterwhich I will get up, dust myself off and move onto another investment. MannKind is not my only investment. If MannKind doesn't fail, it doesn't fail. My investment will grow over time. Now regarding MannKind the company - itself, I have my opinion about management from C CO, C EO right on to C PO there: A) From 2004 through 2016 - completely inept at not only developing Afrezza but commercializing it too. B) From Feb 2016 through July 26, 2017 - far better suited and properly experienced to commercialize and continue researching not only Afrezza but Technosphere as well. That's all there is. Now, respecting whether the current MannKind management team will secure a partner to support commercialization activities in the US or outside of the US, or, successfully raise money through an equity offering or other means, here is my opinion: Refer to B) above. That's all there is. Exactly. A fundamental change is obvious. Many positive things are happening. At this point it is pointless to debate cash burn and what occurred in the past unless you are trying to prevent others from investing, which is not always about the companies books. People's minds are changed through observation and not through argument. Will RogersRegarding point B, and Will Rogers. I observe that the best month for scripts in that period was January 2016. The second best was February 2016. The 3rd best was March 2016. I'm ready for all that preparedness and experience to pay off with more people with diabetes selecting Afrezza.
|
|
|
Post by dreamboatcruise on Jul 26, 2017 16:17:27 GMT -5
For those who forgot where cash may come from before the end of this year... 1. Brazil distribution 2. UAE distribution 3. Locust Walk finds strategic partner for TS 4. One Drop 5. RLS 6. Alternative financing options that are non dilutive (ask new CFO for details) It's not yet approved in UAE or Brazil... and it is not as if scripts will somehow skyrocket the moment it is approved. Just like in the US it will take time for doctors and patients to become aware of Afrezza... and for doctors to get comfortable prescribing it. Won't contribute any meaningful amount of money this year. One Drop doesn't mean more docs will be prescribing. It may be useful marketing. Won't contribute any meaningful amount of money this year. RLS... management has made no mention of time frame for any follow on progress payments whereas they did give time frame for the prior one. I'm guessing with the political shift and noises from justice dept that RLS pipeline may be significantly delayed waiting for clarity on new administrations position/actions. This is just my hunch, but given track record with API partnering, and RLS in particular, I'm guessing that no meaningful amount of money this year. I'm curious what you mean by strategic partner for TS... something beyond a single API? I have been speculating Locust may have been brought in to try to sell TS entirely, with MNKD just retaining license rights for Afrezza. So I think Locust Walk effort is a potential for meaningful money this year... though no slam dunk given MNKDs failure to monetize over the past years. #6... yeah, we'd all love to ask and have answered. I imagine an answer is not forthcoming.
|
|
|
Post by dreamboatcruise on Jul 26, 2017 16:30:18 GMT -5
As sincere as all of the above sounds I will speak for myself. I am fully aware of the cash situation MannKind faces and I am prepared to lose my entire investment. All of it. The advise to sell and preserve what little is left of my long term investment 'rings hollow.' Why? If MannKind fails, it fails. I will lose my entire investment afterwhich I will get up, dust myself off and move onto another investment. MannKind is not my only investment. If MannKind doesn't fail, it doesn't fail. My investment will grow over time. Now regarding MannKind the company - itself, I have my opinion about management from C CO, C EO right on to C PO there: A) From 2004 through 2016 - completely inept at not only developing Afrezza but commercializing it too. B) From Feb 2016 through July 26, 2017 - far better suited and properly experienced to commercialize and continue researching not only Afrezza but Technosphere as well. That's all there is. Now, respecting whether the current MannKind management team will secure a partner to support commercialization activities in the US or outside of the US, or, successfully raise money through an equity offering or other means, here is my opinion: Refer to B) above. That's all there is. Exactly. A fundamental change is obvious. Many positive things are happening. At this point it is pointless to debate cash burn and what occurred in the past unless you are trying to prevent others from investing, which is not always about the companies books. People's minds are changed through observation and not through argument. Will RogersBack in my day we used to actually consider things like balance sheets and cash flow statements when making investment decisions. Thank goodness those are no longer relevant... all that profitability stuff is so tedious. I'll put it all on RED.
|
|